Komipharm International Co (XKRX:041960) LT-Debt-to-Total-Asset : 0.07 (As of Dec. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Komipharm International Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Komipharm International Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.07.

Komipharm International Co's long-term debt to total assets ratio increased from Dec. 2023 (0.04) to Dec. 2024 (0.07). It may suggest that Komipharm International Co is progressively becoming more dependent on debt to grow their business.

Komipharm International Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Komipharm International Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Komipharm International Co LT-Debt-to-Total-Asset Chart

Komipharm International Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.11

0.03

0.04

0.07

Komipharm International Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.04	0.05	0.05	0.07

Komipharm International Co LT-Debt-to-Total-Asset Calculation

Komipharm International Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	9105.701	/	122766.616
	=	0.07

Komipharm International Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	9105.701	/	122766.616
	=	0.07

Komipharm International Co (XKRX:041960) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Komipharm International Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Komipharm International Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Komipharm International Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Komipharm International Co Ltd (XKRX:041960) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

1236-6 Jungwang-Dong, Sihung, Gyeonggi, KOR, 429-450

Website

http://www.komilab.co.kr

Komipharm International Co Ltd is involved in the healthcare sector based in Korea. Its core business includes development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The company produces its products under two divisions: veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle. The other division is made up of veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis and swine erysipelas.

Komipharm International Co Headlines

No Headlines